Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from Pharvaris ( (PHVS) ).
Pharvaris has outlined its strategic priorities for 2025, highlighting the initiation and progress of pivotal Phase 3 studies for deucrictibant, aimed at prophylaxis and on-demand treatment of hereditary angioedema (HAE) attacks. The company is also preparing for the potential commercialization of deucrictibant and expanding its pipeline into treating acquired angioedema due to C1-INH deficiency (AAE-C1INH). Operating from a strong financial position, Pharvaris is committed to advancing its clinical development and enhancing its industry standing, with significant resources allocated for strategic investments and shareholder value. The upcoming data from these studies could potentially bolster Pharvaris’s market position in addressing the needs of patients with these angioedema conditions.
More about Pharvaris
Pharvaris is a late-stage biopharmaceutical company based in Zug, Switzerland, focusing on the development of novel oral bradykinin B2 receptor antagonists. The company addresses unmet medical needs in treating bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema (AAE).
YTD Price Performance: -3.99%
Average Trading Volume: 80,825
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $961.3M
Learn more about PHVS stock on TipRanks’ Stock Analysis page.
